Author: Michelle Dryden

Michelle Dryden has come full-circle back to the exciting world of Journalism, news, and media. Dryden is an Independent Multimedia Journalist. She graduated with honors from Full Sail University. Dryden received the Advanced Achievement Award from Full Sail University's New Media Journalism Master's degree program, in June 2013. With journalism experiences in both digital and traditional journalism since 1996, she is a news veteran. The Media Pub News blog publishes core news and community features. What's your story? Email me at mdryden@themediapub.com. Cheers!!!
Business, Health Care

AdvanSix furthers commitment to sulfur nutrition

Expands Focus on Sulfur Nutrition for Wide Variety of Crops Including Soybeans Robust Operational Performance Supports Improved Granular Conversion Acquires Certain Assets of Commonwealth Industrial Services (CIS), Adding Packaging, Warehousing and Logistics Capabilities PARSIPPANY, N.J. & HOPEWELL, Va. — (BUSINESS WIRE) —

Business, Health Care, Local News

U.S. Food and Drug Administration approves OPDIVO® (nivolumab) in combination with CABOMETYX® (cabozantinib) as first-line treatment for patients with advanced renal cell carcinoma

In CheckMate -9ER, OPDIVO in combination with CABOMETYX doubled median progression-free survival and objective response rate and showed superior overall survival vs. sunitinib1 Approved across all International Metastatic Renal Cell Carcinoma Database Consortium risk categories1,2 Approval expands Company’s presence in first-line advanced